Ironwood Pharmaceuticals, Inc. IRWD
4.85 USD -0.02 (-0.41%)
At closeNov 12, 2026, 5:23 PM EST
4.83 -0.02 -0.39%
After hours · Nov 12, 5:23 PM ET
4.79 Day range 5.00
2.95 52-week range 5.78
- YTD
- +43.92%
- 1 year
- +55.95%
News
zacks.com IRWD Q3 Earnings Beat, Revenues Miss, 2026 View Raised, Stock Up Ironwood's Q3 earnings beat estimates, lifting shares 6.9%, as stronger Linzess sales expectations and profitability drive a higher 2026 outlook.
seekingalpha.com Ironwood Pharmaceuticals, Inc. (IRWD) Q3 2026 Earnings Call Transcript Ironwood Pharmaceuticals, Inc. ( IRWD ) Q3 2026 Earnings Call November 5, 2026 8:30 AM EST Company Participants Chris Stamm - Vice President of Investor Relations & Communications Thomas McCourt -…
marketbeat.com What Ironwood Pharmaceuticals (IRWD) Said on Its Q3 Earnings Call Ironwood Pharmaceuticals NASDAQ: IRWD raised its 2026 financial outlook after third-quarter sales of LINZESS reached $325 million, as improved net pricing and prescription demand supported the…
zacks.com Ironwood Pharmaceuticals (IRWD) Beats Q3 Earnings Estimates Ironwood Pharmaceuticals (IRWD) came out with quarterly earnings of $0.36 per share, beating the Zacks Consensus Estimate of $0.3 per share. This compares to earnings of $0.24 per share a year ago.
benzinga.com Ironwood Pharmaceuticals Q3 2026 Earnings Call Transcript Ironwood Pharmaceuticals (NASDAQ:IRWD) reported third-quarter financial results on Thursday. The transcript from the company’s third-quarter earnings call has been provided below.This transcript is…
benzinga.com Ironwood Pharmaceuticals Raises FY2026 Sales Guidance from $460.000M-$485.000M to $485.000M-$510.000M vs $471.600M Est Ironwood Pharmaceuticals (NASDAQ:IRWD) raises FY2026 sales outlook from $460.000 million-$485.000 million to $485.000 million-$510.000 million vs $471.600 million estimate.
benzinga.com Ironwood Pharmaceuticals Q3 Adj. EPS $0.36 Beats $0.32 Estimate, Sales $133.040M Beat $121.567M Estimate Ironwood Pharmaceuticals (NASDAQ:IRWD) reported quarterly earnings of $0.36 per share which beat the analyst consensus estimate of $0.32 by 12.5 percent. This is a 50 percent increase over earnings…
businesswire.com Ironwood Pharmaceuticals Raises Full-Year 2026 Financial Guidance Driven by Continued LINZESS U.S. Net Sales Growth and Strong Third Quarter Financial Performance BOSTON--(BUSINESS WIRE)--Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD), a biotechnology company developing and commercializing life‑changing therapies for people living with gastrointestinal (GI) and…
defenseworld.net 208,277 Ironwood Pharmaceuticals, Inc. $IRWD Shares Purchased by CWA Asset Management Group LLC CWA Asset Management Group LLC grew its stake in Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) by 71.7% during the third quarter, according to its most recent Form 13F filing with the Securities and…
benzinga.com Ironwood Pharmaceuticals Appoints Tammi Gaskins CEO, Effective Jan. 1, 2027 Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD), a biotechnology company developing and commercializing life-changing therapies for people living with gastrointestinal (GI) and rare diseases, today…
businesswire.com Ironwood Pharmaceuticals Appoints Tammi Gaskins as Chief Executive Officer BOSTON--(BUSINESS WIRE)--Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD), a biotechnology company developing and commercializing life-changing therapies for people living with gastrointestinal (GI) and…
defenseworld.net Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) Stock Rated “Moderate Buy” by Sell-Side Brokerages Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD - Get Free Report) has received a consensus recommendation of "Moderate Buy" from the seven research firms that are presently covering the firm,…
zacks.com Will Linzess Continue to Aid Ironwood's Top-Line Growth in Q3? IRWD's Linzess demand remains strong, with a recent pediatric label expansion and pricing changes poised to support third-quarter 2026 growth.
seekingalpha.com Ironwood Pharmaceuticals: The Stock Is A Call On The Second Apraglutide Trial - Buy Ironwood Pharmaceuticals is rated Buy, but the investment thesis hinges on apraglutide, not Linzess, due to looming generic competition. IRWD's Linzess cash flow is largely committed to debt and…
benzinga.com Ironwood Pharmaceuticals Reports Q2 2026 Results: Full Earnings Call Transcript Ironwood Pharmaceuticals (NASDAQ:IRWD) reported second-quarter financial results on Thursday. The transcript from the company's second-quarter earnings call has been provided below. This content is…
zacks.com PGEN vs. IRWD: Which Biotech Stock Offers Better Growth Potential? Precigen's Papzimeos and Ironwood's Linzess are driving growth, but competition, pipeline progress and single-product reliance shape each biotech's outlook.
zacks.com Ironwood Pharmaceuticals (IRWD) is a Top-Ranked Momentum Stock: Should You Buy? Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
zacks.com 5 Small Drug Stocks Poised to Benefit From a Biotech Recovery INDV, IRWD, RLMD, LRMR and CRDL could offer significant upside as biotech sentiment improves, backed by catalysts and differentiated pipelines.
businesswire.com Ironwood Pharmaceuticals to Participate in the Wells Fargo 21st Annual Healthcare Conference BOSTON--(BUSINESS WIRE)--Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD) today announced that management will participate in a fireside chat at the Wells Fargo 21st Annual Healthcare Conference on…
seekingalpha.com Ironwood Pharmaceuticals: High Dependence On Its Next Trial Ironwood Pharmaceuticals is a small-cap GI-focused biotech with strong LINZESS sales but looming patent expiry by 2029–2030. IRWD raised LINZESS full-year U.S. net sales guidance to $1.15–$1.2…
zacks.com Ironwood Q2 Earnings Beat Estimates, Revenues Lag, 2026 View Raised IRWD tops Q2 earnings estimates, misses on revenues and lifts its 2026 outlook as strong Linzess demand drives year-over-year growth.
seekingalpha.com Ironwood Pharmaceuticals, Inc. (IRWD) Q2 2026 Earnings Call Transcript Ironwood Pharmaceuticals, Inc. (IRWD) Q2 2026 Earnings Call Transcript
marketbeat.com Ironwood Pharmaceuticals Q2 Earnings Call Highlights Ironwood Pharmaceuticals NASDAQ: IRWD reported second-quarter results marked by higher LINZESS sales, the start of enrollment in its confirmatory Phase III study of apraglutide, and repayment of its…
zacks.com Ironwood Pharmaceuticals (IRWD) Q2 Earnings Top Estimates Ironwood Pharmaceuticals (IRWD) came out with quarterly earnings of $0.31 per share, beating the Zacks Consensus Estimate of $0.26 per share. This compares to earnings of $0.14 per share a year ago.
gurufocus.com Ironwood Pharmaceuticals Raises 2026 Full-Year Financial Guidance Building on Strong Second Quarter Results [url="]Ironwood Pharmaceuticals, Inc.[/url] (Nasdaq: IRWD), a biotechnology company developing and commercializing lifeâchanging therapies for people living w- benzinga.com Ironwood Pharmaceuticals Raises FY2026 Sales Guidance from $450.000M-$475.000M to $460.000M-$485.000M vs $460.118M Est Ironwood Pharmaceuticals (NASDAQ:IRWD) raises FY2026 sales outlook from $450.000 million-$475.000 million to $460.000 million-$485.000 million vs $460.118 million estimate.
benzinga.com Ironwood Pharmaceuticals Q2 Adj. EPS $0.31 Misses $0.36 Estimate, Sales $113.041M Miss $114.844M Estimate Ironwood Pharmaceuticals (NASDAQ:IRWD) reported quarterly earnings of $0.31 per share which missed the analyst consensus estimate of $0.36 by 13.89 percent. This is a 121.43 percent increase over…- benzinga.com Ironwood Pharma Initiates Phase 3 STARS‑2 Trial Of Apraglutide In Short Bowel Syndrome With Intestinal Failure – Ironwood Chief Medical Officer and Head of Research and Drug Development Dr. Michael Shetzline to Retire After 30-Year Career Advancing GI Science and Patient Care –– Dr. Silber, a Drug Development…
benzinga.com 12 Health Care Stocks Moving In Tuesday's After-Market Session Gainers Catheter Precision (AMEX:VTAK) shares moved upwards by 34.7% to $0.96 during Tuesday's after-market session. The company's market cap stands at $2.0 million. Ironwood Pharmaceuticals…- benzinga.com Ironwood Pharma Says FDA Approves Use Of LINZESS In Pediatric Patients 2 Years Of Age And Older With Functional Constipation – Expanded indication extends availability to children ages 2-5 with FC; previously approved in pediatric patients 6 years of age and older –– LINZESS remains the first-and-only FDA-approved…
benzinga.com Ironwood Pharmaceuticals Affirms FY2026 Sales Guidance of $450.000M-$475.000M vs $458.593M Est Ironwood Pharmaceuticals (NASDAQ:IRWD) affirms FY2026 sales outlook from $450.000 million-$475.000 million to $450.000 million-$475.000 million vs $458.593 million estimate.
benzinga.com Ironwood Pharmaceuticals Q1 Adj. EPS $0.24, Inline, Sales $106.506M Beat $92.088M Estimate Ironwood Pharmaceuticals (NASDAQ:IRWD) reported quarterly earnings of $0.24 per share which met the analyst consensus estimate. This is a 271.43 percent increase over losses of $(0.14) per share from…- benzinga.com Ironwood Pharmaceuticals Presents New Findings From Survey Assessing Healthcare Provider Perspectives On The Use Of Total Parenteral Nutrition In The Treatment Of Short Bowel Syndrome Surveyed HCPs emphasized the importance of reducing patient dependence on TPN to improve quality of life, reduce line infections and lower the risk of thrombosis. The majority (46.4%) identified…
benzinga.com Avanos Medical, Travere Therapeutics, Globalstar And Other Big Stocks Moving Higher On Tuesday Dow Jones up 200 points, Avanos Medical Inc rose on going-private deal. Big gainers include AVNS, TVTX, BE, IONQ, SANA, RGTI, VACH, AOSL.
benzinga.com Citizens Maintains Market Outperform on Ironwood Pharmaceuticals, Raises Price Target to $10 Citizens analyst Jason N. Butler maintains Ironwood Pharmaceuticals (NASDAQ:IRWD) with a Market Outperform and raises the price target from $8 to $10.
benzinga.com 12 Health Care Stocks Moving In Wednesday's Intraday Session - benzinga.com Ironwood Pharmaceuticals Affirms FY2026 Sales Guidance of $450.000M-$475.000M Ironwood Pharmaceuticals (NASDAQ:IRWD) affirms FY2026 sales outlook from $450.000 million-$475.000 million to $450.000 million-$475.000 million.
- benzinga.com Ironwood Pharmaceuticals Q4 Adj. EPS $(0.01) Misses $0.01 Estimate, Sales $47.709M Miss $50.933M Estimate Ironwood Pharmaceuticals (NASDAQ:IRWD) reported quarterly losses of $(0.01) per share which missed the analyst consensus estimate of $0.01 by 200 percent. This is a 200 percent decrease over earnings…
benzinga.com Earnings Scheduled For February 25, 2026 
benzinga.com Insights into Ironwood Pharmaceuticals's Upcoming Earnings - benzinga.com Wells Fargo Maintains Equal-Weight on Ironwood Pharmaceuticals, Raises Price Target to $5 Wells Fargo analyst Mohit Bansal maintains Ironwood Pharmaceuticals (NASDAQ:IRWD) with a Equal-Weight and raises the price target from $3 to $5.
benzinga.com Stock Market Today: S&P 500, Nasdaq, WTI Crude Futures Advance After US Strike On Venezuela— GH Research, Vertiv Holdings, Nukkleus In Focus (UPDATED) (Editor’s note: The future prices of benchmark tracking ETFs, the lede, and the headline were updated in the story.) U.S. stock futures rose in the first full trading week of the year on Monday after…
benzinga.com Why Intelligent Bio Solutions Shares Are Trading Lower By Around 20%? Here Are Other Stocks Moving In Friday's Mid-Day Session 
benzinga.com Crude Oil Falls 1%; US Manufacturing Growth Eases In December - benzinga.com 12 Health Care Stocks Moving In Friday's Intraday Session
benzinga.com Ironwood Pharmaceuticals, Baidu, Vertiv Holdings And Other Big Stocks Moving Higher On Friday 
benzinga.com Ironwood Pharma Stock Rallies On Strong 2026 Outlook Ironwood Pharmaceuticals (IRWD) stock rose with high volume on Friday, releasing financial guidance for 2026.
benzinga.com US Stocks Mixed; Dow Falls Over 100 Points 
benzinga.com Urban Outfitters, Arrowhead Pharmaceuticals, Petco Health and Wellness And Other Big Stocks Moving Higher On Wednesday - benzinga.com Wells Fargo Maintains Equal-Weight on Ironwood Pharmaceuticals, Raises Price Target to $3 Wells Fargo analyst Mohit Bansal maintains Ironwood Pharmaceuticals (NASDAQ:IRWD) with a Equal-Weight and raises the price target from $1 to $3.